Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ziihera (zanidatamab-hrii)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BeOne Medicines, Jazz, Zymeworks

Drug class:

HER2 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

mobocertinib (12)

trastuzumab-dttb (11)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

sunvozertinib (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

sevabertinib (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

diznalimgene lisbac (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

pertuzumab-dpzb (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 positive	Biliary Tract Cancer	HER-2 positive	Biliary Tract Cancer	zanidatamab-hrii Sensitive: A1 - Approval zanidatamab-hrii Sensitive : A1	zanidatamab-hrii Sensitive: A1 - Approval zanidatamab-hrii Sensitive : A1
HER-2 expression	Biliary Tract Cancer	HER-2 expression	Biliary Tract Cancer	zanidatamab-hrii Sensitive: B - Late Trials zanidatamab-hrii Sensitive : B	zanidatamab-hrii Sensitive: B - Late Trials zanidatamab-hrii Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	zanidatamab-hrii Sensitive: C1 - Off-label zanidatamab-hrii Sensitive : C1	zanidatamab-hrii Sensitive: C1 - Off-label zanidatamab-hrii Sensitive : C1
HER-2 amplification	Biliary Tract Cancer	HER-2 amplification	Biliary Tract Cancer	zanidatamab-hrii Sensitive: C2 – Inclusion Criteria zanidatamab-hrii Sensitive : C2	zanidatamab-hrii Sensitive: C2 – Inclusion Criteria zanidatamab-hrii Sensitive : C2
HER-2 overexpression	Biliary Tract Cancer	HER-2 overexpression	Biliary Tract Cancer	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3
HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3
HER-2 overexpression	Gastroesophageal Cancer	HER-2 overexpression	Gastroesophageal Cancer	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	tislelizumab-jsgr + zanidatamab-hrii Sensitive: C3 – Early Trials tislelizumab-jsgr + zanidatamab-hrii Sensitive : C3	tislelizumab-jsgr + zanidatamab-hrii Sensitive: C3 – Early Trials tislelizumab-jsgr + zanidatamab-hrii Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	tislelizumab-jsgr + zanidatamab-hrii Sensitive: C3 – Early Trials tislelizumab-jsgr + zanidatamab-hrii Sensitive : C3	tislelizumab-jsgr + zanidatamab-hrii Sensitive: C3 – Early Trials tislelizumab-jsgr + zanidatamab-hrii Sensitive : C3
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	palbociclib + zanidatamab-hrii Sensitive: C3 – Early Trials palbociclib + zanidatamab-hrii Sensitive : C3	palbociclib + zanidatamab-hrii Sensitive: C3 – Early Trials palbociclib + zanidatamab-hrii Sensitive : C3